Portola Pharmaceuticals, Inc. announced that Tao Fu, chief commercial officer, has resigned effective September 21, 2018 to pursue opportunities outside the company. During the transition period, Mardi C. Dier, interim co-president and chief financial officer, will lead the company’s commercial activities, including the ongoing launches of Andexxa® and Bevyxxa®. The company will also continue to leverage the external strategic counsel provided by its Commercial Advisory Committee, comprising members of the company’s Board of Directors and expert industry consultants. Mr. Fu will remain a consultant to the company until March 1, 2019 to assist in the transition of his responsibilities.